Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 3 | BMC Cancer

Fig. 3

From: Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients

Fig. 3

Genomic heterogeneity of bladder cancer CTCs. Plots of whole genome CNV profiles of five CK/CD45/PD-L1+ CTCs from patient B-022 (a-e). X axis: chromosomes displayed as from chromosome 1 to 22, X and Y (from left to right, shifted by red and blue color); Y axis: normalized log2 transformed ratio of copy number of test sample over that of WBC control. Five CTCs show various genomic aberrations a loss of chromosome 1, 2, 17, 18, and 20; b loss of chromosome 6; c gain of chromosome 21; d and e gain of chromosome X and loss of chromosome Y. f Ploidy analysis for genomic aberrations from NSG seen in CTC (b), predicted ploidy = 3.25

Back to article page